Type 1 Diabetes Clinical Trial
Official title:
Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus
A tonic active epithelial Na+ channel (ENaC) in pre-eclampsia (PE) escaped normal hormonal control may offer an attractive explanatory model for the pathophysiology of established PE. The channel is activated by plasmin. Microalbuminuria predicts the development of pre-eclampsia in pregnant patients with pregestational diabetes type 1. The investigators hypothesize that urine-plasmin excreted in the kidneys, when proteinuria occurs, could be the cause. The investigators want to test the correlation between measurable plasmin/plasminogen in the urine early in pregnancy and the development of preeclampsia in pregnant patients with type 1 diabetes.
Study aim and hypothesis:
Aim:
To test whether there is a measurable correlation between plasmin/plasminogen, abnormally
excreted in the kidneys, and the development of pre-eclampsia in pregnant women with Type 1
diabetes.
Hypothesis:
1. The amount of proteases ( plasmin/plasminogen ), excreted in urine, predicts development
of preeclampsia in pregnant patients with type 1 diabetes.
If a correlation between excreted plasmin/plasminogen, in urine, in patients with type 1
diabetes and development of preeclampsia, are seen, proteases might be used as a marker for
pre-eclampsia in this group of patients. Prospectively perhaps also as a marker for disease
severity.
In these high risk groups it is possible that outpatient visits could be optimized and thus
lower the amount of preterm births.
Study design:
The study is an observational, longitudinal - prospective study. Women with pregestational
type 1 diabetes are included when they show up for their first outpatient pregnancy visit
around pregnancy week 9.
Selection of patients:
Patients are selected from Gynecological- obstetric department, Aarhus University hospital -
Skejby, and Gynecological- Obstetric department, Odense University Hospital. To be included
they must be singleton-pregnant, have turned 18 years and have Type 1 diabetes.
Background information:
Date of birth, sex, weight, height, BMI, smoking status, current medical treatment, duration
of diabetes and parity are registered.
Length of gestation, placental weight, way of delivery (natural birth or cesarean section),
umbilical cord pH, apgar score and infant weight are registered post-partum.
Effect variables:
Clinical:
Weight, height, BMI, smoking status, microalbuminuria/proteinuria. Blood pressure (systolic,
diastolic, mean arterial pressure). Weight of placenta.
Blood test measurements:
Se-creatinine, p-Na+, p-K+. P-plasminogen, P-albumin, Aldosterone.
Measurements in 50 ml "spot urine":
Plasmin, plasminogen, ENaC peptide fragment (analyses in location of development,)
Proteolytic activity, Prostatin, Creatinine, Na+, K+, Aldosterone, Albumin
Study process:
Collection of blood- and spot-urine samples:
Urine-samples are collected in pregnancy week 9-14. Blood pressure is measured. Samples and
blood-pressures are re-collected in pregnancy-week 20, 28,32, 36 and perhaps 38.
Following outcomes are observed: Development of preeclampsia, defined by hypertension ( >
140/90 mmHg), and proteinuria ( >0,3 g/24 hour). Preterm delivery and light for gestational
age.
Data- analysis methods:
This is an observational longitudinal-prospective study which includes approximately 130
pregnant patients with Type 1 diabetes. Patients are included from Skejby and Odense
University Hospitals in cooperation.
Results are evaluated statistically by uni - and multivariate logistic regression analysis.
Population size estimation:
Similar (Danish) observational prospective studies on urine- biomarkers (including albumin)
ability to predict preeclampsia/preterm delivery, in patients with pre-gestational type 1
diabetes, have been made. They achieved high significance data with spot-samples of 130 -170
patients. With the participation of two centers it seems realistic and adequately to include
130 patients within the settings of a Ph. D. study. Every year an amount of 50-60 patients
are seen in the outpatient ward at Skejby- and Odense University Hospitals (in all
approximately 100-120 patients).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |